SHARJAH-ART-FOUNDATION
7.3.2019 18:28:04 CET | Business Wire | Press release
Under the patronage of His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, the 14th edition of Sharjah Biennial (SB14) commenced on Thursday at the Sharjah Art Foundation (SAF) Art Spaces in Al Mureijah.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190307005593/en/
SB14, held this year under the title ‘Leaving the Echo Chamber’, will feature three distinct exhibitions; Zoe Butt’s exhibition Journey Beyond The Arrow; Omar Kholeif’s Making New Time and Claire Tancons’ Look for Me All Around You.
SB14 features over 80 established and emerging artists from around the globe, including over 60 new commissions, as well as many never-before-seen works that will displayed in various locations across the emirate of Sharjah, the Mureijah Square and the Arts Square, as well as in SAF’s studios in Al Hamriyah, in the East Coast city of Kalba and other spaces in Umm Al Quwain.
The Sharjah Art Foundation is also organizing the 12th edition of the March Meeting 2019, from 9 -11 March, 2019 at the Sharjah Institute of Theatrical Arts in Al Mureijah, which will include panel discussions, performances, films and artistic productions, in line with the themes of the three exhibitions at SB14.
SB14 will also feature independent film screenings for film lovers in the UAE; as well as educational programs, aligned with this year’s theme ‘Leaving the Echo Chamber’.
Programs intended for adults and children include workshops on photography, drawing, writing and theatrical performance. Other workshops for ‘People of determination’ provide a variety of topics on photography skills, puppetry, drawing, musical instruments and Islamic art; while the schools and youth centers’ program offers a set of workshops and field trips on topics such as abstract art, architecture and storytelling.
SB14 is made possible through the generous support of Van Cleef & Arples (Gold Sponsor) and Crescent Petroleum (Silver Sponsor). In-kind support is offered by Sharjah Municipality, Sharjah Roads and Transport Authority; Sharjah Electricity and Water Authority; Bee'ah, the Dubai Economic Department; the Institut Français in the UAE and the Institut Français in France.
The Sharjah Biennial is the most important cultural event in the Arab world and, since its inception in 1993, has been instrumental in supporting the arts landscape in the UAE and the region.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005593/en/
Contact:
Hussain Al Mulla , Media Relations Executive +971563980067 Hussain.AlMulla@SGMB.ae
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
